Molecular mechanisms of peripartum cardiomyopathy: A vascular/hormonal hypothesis

Trends in Cardiovascular Medicine

Volumn 25, Issue 6, 2015, Pages 499-504

  Bello, Natalie A ^a   Arany, Zoltan ^b  

^a NewYork Presbyterian Hospital   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; HYPERTENSIVE FACTOR; MANGANESE SUPEROXIDE DISMUTASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PROLACTIN; REACTIVE OXYGEN METABOLITE; STAT3 PROTEIN; VASCULOTROPIN RECEPTOR 1; PROGESTERONE;

ADULT; CASE REPORT; CONGESTIVE HEART FAILURE; ECHOCARDIOGRAPHY; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; INCIDENCE; PERIPARTUM CARDIOMYOPATHY; PREECLAMPSIA; PRIORITY JOURNAL; REVIEW; GESTATIONAL AGE; HEART FAILURE, SYSTOLIC; MATERNAL DEATH; METABOLISM; MOLECULAR BIOLOGY; MORTALITY; PATHOPHYSIOLOGY; PERINATAL PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; RARE DISEASE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TRENDS; VASCULAR DISEASE;

ADULT; FEMALE; GESTATIONAL AGE; HEART FAILURE, SYSTOLIC; HUMANS; MATERNAL DEATH; MOLECULAR BIOLOGY; PERIPARTUM PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PROGESTERONE; RARE DISEASES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; VASCULAR DISEASES;

EID: 84939266912     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2015.01.004     Document Type: Review

References (54)

1. Arany Z.P., Walker C.M., Wang L. Case records of the Massachusetts General Hospital. Case 22-2014. A 40-year-old woman with postpartum dyspnea and hypoxemia. N Engl J Med 2014, 371:261-269.
2. Ritchie C. Clinical contribution to the pathology, diagnosis, and treatment of certain chronic diseases of the heart. Edinburgh Med Surg J 1849, 2:333-342.
3. Pearson G.D., Veille J., Rahimtoola S., Hsia J., Oakley C.M., Hosenpud J.D., et al. Peripartum cardiomyopathy: National heart, lung, and blood institute and office of rare diseases (National Institutes of Health) workshop recommendations and review. J Am Med Assoc 2000, 283:1183-1188.
4. Sliwa K., Hilfiker-Kleiner D., Petrie M.C., Mebazaa A., Pieske B., Buchmann E., et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail 2010, 12:767-778.
5. Brar S.S., Khan S.S., Sandhu G.K., Jorgensen M.B., Parikh N., Hsu J.W.Y., et al. Incidence, mortality, and racial differences in peripartum cardiomyopathy. Am J Cardiol 2007, 100:302-304.
6. Deneux-Tharaux C., Berg C., Bouvier-Colle M.H., Gissler M., Harper M., Nannini A., et al. Underreporting of pregnancy-related mortality in the United States and Europe. Obstet Gynecol 2005, 106:684-692.
7. Fett J.D., Christie L.G., Carraway R.D., Murphy J.G. Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Clinic Proc 2005, 80:1602-1606.
8. Isezuo S.A., Abubakar S.A. Epidemiologic profile of peripartum cardiomyopathy in a tertiary care hospital. Ethn Dis 2007, 17:228-233.
9. Goland S.M.K., Hatamizadeh P., Elkayam U. Differences in clinical profile of African-American women with peripartum cardiomyopathy in the United States. J Card Fail 2013, 19:214-218.
10. Fett J.D., Murphy J.G. Infant survival in Haiti after maternal death from peripartum cardiomyopathy. Int J Gynaecol Obstet 2006, 94:135-136.
11. Gentry M.B., Dias J.K., Luis A., Patel R., Thornton J., Reed G.L. African-American women have a higher risk for developing peripartum cardiomyopathy. J Am Coll Cardiol 2010, 55:654-659.
12. Desai D., Moodley J., Naidoo D. Peripartum cardiomyopathy: experiences at King Edward VIII Hospital, Durban, South Africa and a review of the literature. Trop Doct 1995, 25:118-123.
13. Abboud J., Murad Y., Chen-Scarabelli C., Saravolatz L., Scarabelli T.M. Peripartum cardiomyopathy: a comprehensive review. Int J Cardiol 2007, 118:295-303.
14. Brown C.S., Bertolet B.D. Peripartum cardiomyopathy: a comprehensive review. Am J Obstet Gynecol 1998, 178:409-414.
15. Desai P. Peripartum Cardiomyopathy: a review. J Obstet Gynecol India 2010, 60:25-32.
16. Johnson-Coyle L., Jensen L., Sobey A. Peripartum cardiomyopathy: review and practice guidelines. Am J Crit Care 2012, 21:89-99.
17. Karaye K.M., Henein M.Y. Peripartum cardiomyopathy: a review article. Int J Cardiol 2011, 164:333-338.
18. Ntusi N.B.A., Mayosi B.M. Aetiology and risk factors of peripartum cardiomyopathy: a systematic review. Int J Cardiol 2009, 131:168-179.
19. Hunt S.A., Abraham W.T., Chin M.H., Feldman A.M., Francis G.S., Ganiats T.G., et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009, 53:e1-e90.
20. Hunt S.A. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005, 46:e1-e82.
21. Blauwet L.A., Libhaber E., Forster O., Tibazarwa K., Mebazaa A., Hilfiker-Kleiner D., et al. Predictors of outcome in 176 South African patients with peripartum cardiomyopathy. Heart 2012, 99:308-313.
22. Haghikia A., Podewski E., Libhaber E., Labidi S., Fischer D., Roentgen P., et al. Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. Basic Res Cardiol 2013, 108:366.
23. Zimmerman H., Bose R., Smith R., Copeland J.G. Treatment of peripartum cardiomyopathy with mechanical assist devices and cardiac transplantation. Ann Thorac Surg 2010, 89:1211-1217.
24. Pillarisetti J., Kondur A., Alani A., Reddy M., Reddy M., Vacek J., et al. Peripartum cardiomyopathy: predictors of recovery and current state of implantable cardioverter-defibrillator use. J Am Coll Cardiol 2014, 63(25 Pt A):2831-2839.
25. Elkayam U. Risk of subsequent pregnancy in women with a history of peripartum cardiomyopathy. J Am Coll Cardiol 2014, 64:1629-1636.
26. Amos A.M., Jaber W.A., Russell S.D. Improved outcomes in peripartum cardiomyopathy with contemporary. Am Heart J 2006, 152:509-513.
27. Chee K.H. Favourable outcome after peripartum cardiomyopathy: a ten-year study on peripartum cardiomyopathy in a university hospital. Singapore Med J 2013, 54:28-31.
28. Homans D.C. Peripartum cardiomyopathy. N Engl J Med 1985, 312:1432-1437.
29. Sliwa K., Forster O., Libhaber E., Fett J.D., Sundstrom J.B., Hilfiker-Kleiner D., et al. Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur Heart J 2006, 27:441-446.
30. Sliwa K., Skudicky D., Bergemann A., Candy G., Puren A., Sareli P. Peripartum cardiomyopathy: analysis of clinical outcome, left ventricular function, plasma levels of cytokines and Fas/APO-1. J Am Coll Cardiol 2000, 35:701-705.
31. Hilfiker-Kleiner D., Sliwa K., Drexler H. Peripartum cardiomyopathy: recent insights in its pathophysiology. Trends Cardiovasc Med 2008, 18:173-179.
32. Halkein J., Tabruyn S.P., Ricke-Hoch M., Haghikia A., Nguyen N.Q., Scherr M., et al. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J Clin Invest 2013, 123:2143-2154.
33. Bajou K., Herkenne S., Thijssen V.L., D'Amico S., Nguyen N.Q., Bouche A., et al. PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16k prolactin. Nat Med 2014, 20:741-747.
34. Sliwa K., Blauwet L., Tibazarwa K., Libhaber E., Smedema J.P., Becker A., et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation 2010, 121:1465-1473.
35. Patten I.S., Rana S., Shahul S., Rowe G.C., Jang C., Liu L., et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature 2012, 485:333-338.
36. Arany Z., Foo S.Y., Ma Y., Ruas J., Bommi-Reddy A., Girnun G.D., et al. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1α. Nature 2008, 451:1008-1012.
37. Powe C.E., Levine R.J., Karumanchi S.A. Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation 2011, 123:2856-2869.
38. Melchiorre K., Sutherland G.R., Baltabaeva A., Liberati M., Thilaganathan B. Maternal cardiac dysfunction and remodeling in women with preeclampsia at term. Hypertension 2011, 57:85-93.
39. Melchiorre K., Sutherland G.R., Liberati M., Thilaganathan B. Preeclampsia is associated with persistent postpartum cardiovascular impairment. Hypertension 2011, 58:709-715.
40. Shahul S., Rhee J., Hacker M.R., Gulati G., Mitchell J.D., Hess P., et al. Subclinical left ventricular dysfunction in preeclamptic women with preserved left ventricular ejection fraction: a 2D speckle-tracking imaging study. Circ Cardiovasc Imaging 2012, 5:734-739.
41. Bello N., Rendon I.S., Arany Z. The relationship between pre-eclampsia and peripartum cardiomyopathy: a systematic review and meta-analysis. J Am Coll Cardiol 2013, 62:1715-1723.
42. Kamiya C.A., Kitakaze M., Ishibashi-Ueda H., Nakatani S., Murohara T., Tomoike H., et al. Different characteristics of peripartum cardiomyopathy between patients complicated with and without hypertensive disorders. Results from the Japanese Nationwide survey of peripartum cardiomyopathy. Circ J 2011, 75:1975-1981.
43. Kao D.P., Hsich E., Lindenfeld J. Characteristics, adverse events, and racial differences among delivering mothers with peripartum cardiomyopathy. JACC Heart Fail 2013, 1:409-416.
44. Elkayam U., Akhter M.W., Singh H., Khan S., Bitar F., Hameed A., et al. Pregnancy-associated cardiomyopathy: clinical characteristics and a comparison between early and late presentation. Circulation 2005, 111:2050-2055.
45. Bdolah Y., Lam C., Rajakumar A., Shivalingappa V., Mutter W., Sachs B.P., et al. Twin pregnancy and the risk of preeclampsia: bigger placenta or relative ischemia?. Am J Obstet Gynecol 2008, 198. (428 e1-e6).
46. Rajakumar A., Michael H.M., Rajakumar P.A., Shibata E., Hubel C.A., Karumanchi S.A., et al. Extra-placental expression of vascular endothelial growth factor receptor-1, (Flt-1) and soluble Flt-1 (sFlt-1), by peripheral blood mononuclear cells (PBMCs) in normotensive and preeclamptic pregnant women. Placenta 2005, 26:563-573.
47. Liu L.X., Arany Z. Maternal cardiac metabolism in pregnancy. Cardiovasc Res 2014, 101:545-554.
48. Ruys T.P., Roos-Hesselink J.W., Hall R., Subirana-Domenech M.T., Grando-Ting J., Estensen M., et al. Heart failure in pregnant women with cardiac disease: data from the ROPAC. Heart 2014, 100:231-238.
49. Horne B.D., Rasmusson K.D., Alharethi R., Budge D., Brunisholz K.D., Metz T., et al. Genome-wide significance and replication of the chromosome 12p11.22 locus near the PTHLH gene for peripartum cardiomyopathy. Circ Cardiovasc Genet 2011, 4:359-366.
50. Bakre M.M., Zhu Y., Yin H., Burton D.W., Terkeltaub R., Deftos L.J., et al. Parathyroid hormone-related peptide is a naturally occurring, protein kinase A-dependent angiogenesis inhibitor. Nat Med 2002, 8:995-1003.
51. van Spaendonck-Zwarts K.Y., van Tintelen J.P., van Veldhuisen D.J., van der Werf R., Jongbloed J.D., Paulus W.J., et al. Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy. Circulation 2010, 121:2169-2175.
52. van Spaendonck-Zwarts K.Y., Posafalvi A., van den Berg M.P., Hilfiker-Kleiner D., Bollen I.A., Sliwa K., et al. Titin gene mutations are common in families with both peripartum cardiomyopathy and dilated cardiomyopathy. Eur Heart J 2014, 35:2165-2173.
53. Hagberg C.E., Falkevall A., Wang X., Larsson E., Huusko J., Nilsson I., et al. Vascular endothelial growth factor B controls endothelial fatty acid uptake. Nature 2010, 464:917-921.
54. Venkatesha S., Toporsian M., Lam C., Hanai J., Mammoto T., Kim Y.M., et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006, 12:642-649.